The investigation centered on comparing two genetically defined cancer cell cultures derived from models of NSCLC: the ATF4-high KP-O and the ATF4-low KP-Y populations. Initial drug screening revealed a surprising specificity in their metabolic dependencies. While both were unresponsive to inhibitors targeting various amino acid transporters and metabolic enzymes such as SLC7A11, BCAT, or PHGDH, KP-O cultures exhibited heightened sensitivity to glutamine deprivation and treatment with DON, a glutamine analogue toxic to cancer cells. This disparity underscores the pivotal role of glutamine metabolism in determining therapeutic responses.

Delving deeper, the focus shifted towards targeting glutaminolysis—the conversion of glutamine to glutamate—central to cellular bioenergetics and biosynthesis. The study employed glutaminase inhibitors (GLSi) CB-839 (telaglenastat) and BPTES, agents capable of halting this rate-limiting step. Remarkably, KP-O cells demonstrated pronounced sensitivity to both drugs, linking high ATF4 expression and glutaminolysis dependency. Additionally, antagonism of ASCT2, the principal glutamine transporter using V-9302, mirrored this effect, further accentuating glutamine’s indispensable role in sustaining KP-O cell viability.

Mechanistic exploration through metabolic rescue experiments painted a nuanced picture of glutamate’s centrality. Pretreatment of KP-O cultures with dimethyl-2-oxoglutarate (DMG), a cell-permeable α-ketoglutarate analog that replenishes critical TCA cycle intermediates, or pyruvate derived from glucose metabolism, effectively reversed sensitivity to CB-839. This rescue was unique as other tested metabolites or antioxidants failed to confer protection, except for erastin, a cysteine–glutamate antiporter system inhibitor. These findings emphatically pinpointed glutamate exhaustion rather than downstream metabolic disruptions as the culprit for GLSi-induced cytotoxicity in KP-O cultures.

Critical to the narrative is the integral role played by ATF4. Genetic ablation or pharmacological attenuation of ATF4 activity using ISRIB (Integrated Stress Response Inhibitor) rendered KP-O cells resistant to CB-839, underscoring the dependency of glutaminase sensitivity on this transcription factor. Conversely, forced ATF4 overexpression in the historically resistant KP-Y cultures conferred newfound vulnerability to GLS inhibition, demonstrating a causal relationship. This interplay also extended to 3D tumor spheroid models: KP-O spheroids lost their characteristic anoikis resistance—a hallmark of metastatic potential—upon GLSi or V-9302 treatment, a defect that was likewise reversed when ATF4 was inhibited.

From a translational perspective, in vivo experiments confirmed the therapeutic promise of targeting glutaminolysis within the metastatic microenvironment. Intravenous transplantation of KP-O cultures into murine hosts resulted in aggressive lung metastasis under vehicle treatment but was nearly abolished with CB-839 administration. Strikingly, KP-Y cells implanted similarly evoked minimal metastatic burden regardless of treatment, demonstrating specificity. Notably, CB-839 did not impede the primary tumor growth in either model following subcutaneous transplantation, a divergence highlighting the metastasis-focused effectiveness of GLS inhibition.

Quantitative assessments endorsed these observations, with CB-839 treatment virtually eradicating distant metastases from KP-O tumors without affecting their primary mass or growth kinetics. This selective suppression of metastatic seeding or outgrowth, sparing tumor proliferation, suggests a unique dependency of metastatic cells on glutaminolysis mediated by ageing and ATF4 activation. These insights may explain the clinical challenges in treating metastasis and underscore the need for tailored metabolic interventions targeting this axis.

This study pioneers the conceptual junction where ageing biology intersects with cancer metabolism and metastasis. The integrated stress response, governed by ATF4, commandeers metabolic rewiring that fosters metastatic competence through glutamine and glutamate utilization. By exploiting this axis using clinically relevant GLS inhibitors, such as CB-839, there appears to be a viable strategy to thwart metastasis specifically in cancers with elevated ATF4 signaling—a phenotype enriched in aged patients.

Future clinical translation of these findings could revolutionize NSCLC management in older demographics, where current therapies exhibit limited efficacy against metastatic disease. It reveals how stress-adaptive transcription factors reshape metabolic landscapes within tumors, creating transient but exploitable vulnerabilities. Moreover, it invites broader applications across cancers exhibiting stress response hyperactivation, potentially heralding a new class of metabolically targeted anti-metastatic agents.

In summary, the novel identification of ageing-induced ATF4-dependent glutamine addiction in metastatic NSCLC cells presents a compelling target for intervention. GLS inhibitors, currently progressing through clinical trials, may find renewed focus as adjuvants to prevent metastatic progression rather than solely tumor reduction. This paradigm shift champions metabolic stress signaling as the Achilles’ heel of metastatic dissemination, reshaping therapeutic paradigms in oncology.

The study’s rigorous integration of cellular, molecular, and in vivo models highlights the precision with which cancer metabolism can be therapeutically manipulated. The metabolic plasticity modulated by ATF4 not only sustains metastasis but unveils a highly selective, context-dependent vulnerability. In doing so, it sets a precedent for unraveling complex age-related oncogenic programs through metabolic intervention, promising enhanced survivorship and quality of life for patients burdened by aggressive lung cancers.

As this research lays the groundwork for targeted metabolic therapies, it also prompts vital questions about long-term effects, resistance mechanisms, and patient stratification. The intersection of ageing biology with cancer therapeutics will undoubtedly continue to burgeon, catalyzing innovative strategies that are as complex and adaptive as the disease they aim to conquer.

Subject of Research: Metabolic rewiring driven by ATF4 in ageing and its impact on metastasis in non-small cell lung cancer.

Article Title: Ageing promotes metastasis via activation of the integrated stress response.

Article References:
Patel, A.A.H., Dzanan, J.J., Ali, K.X. et al. Ageing promotes metastasis via activation of the integrated stress response. Nature (2026). https://doi.org/10.1038/s41586-026-10216-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10216-0

Colorectal cancer, one of the leading causes of cancer-related morbidity worldwide, remains a formidable clinical challenge due to its heterogeneity and adaptive resistance to conventional therapies. Recent efforts have centered on unraveling the molecular underpinnings that sustain tumor growth and metastatic potential. hnRNP A1, a well-known RNA-binding protein involved in diverse aspects of RNA metabolism including splicing, transport, and stability, has now been identified as a critical player that acts as a molecular brake on colorectal cancer progression.

This study, conducted by Ji, K., Zhou, L., Zhang, T., and colleagues, presents compelling evidence that hnRNP A1 exerts tumor-suppressive effects via regulation of lipid metabolic pathways—specifically fatty acid metabolism—which are crucial to cancer cell survival and proliferation. Altered lipid metabolism is a hallmark of cancer, enabling malignant cells to meet their heightened bioenergetic and biosynthetic demands. By modulating this metabolic circuitry, hnRNP A1 disrupts the balance necessary for tumor maintenance.

Through rigorous experimental models, including in vitro colorectal cancer cell lines and in vivo tumorigenesis assays, the research group demonstrated that elevated hnRNP A1 expression correlated with restrained tumor growth rates and attenuated metastatic capabilities. Mechanistically, hnRNP A1 appears to stabilize the transcripts of key enzymes involved in fatty acid catabolism, thereby enhancing their expression and function. This shift promotes metabolic remodeling unfriendly to cancer sustenance.

One of the pivotal insights from the study was how hnRNP A1 influences RNA stability. By binding to the 3′ untranslated regions (3′ UTR) of specific mRNAs encoding fatty acid metabolism enzymes, hnRNP A1 increased their half-life, ensuring sustained catalytic activity. This post-transcriptional regulatory mechanism pinpoints hnRNP A1 as a lynchpin in linking metabolic control with gene expression fidelity, highlighting the nuanced layers of regulation operative in cancer cells.

Moreover, patient-derived colorectal tumor samples analyzed in this study revealed a striking inverse relationship between hnRNP A1 levels and tumor aggressiveness. Lower expression of hnRNP A1 correlated with more advanced disease stages and poorer prognosis. This clinical association underscores the protein’s potential as a prognostic biomarker that might inform patient stratification and guide personalized therapy.

The study also ventured into therapeutic territory, exploring strategies to restore or mimic hnRNP A1 function in colorectal cancer models. Experimental overexpression of hnRNP A1 curtailed tumor cell proliferation and induced apoptotic cascades, a finding that opens the door for the development of novel agents that can activate or enhance hnRNP A1 activity. This therapeutic angle is particularly promising given the current lack of targeted treatments specifically addressing metabolic dysregulation in colorectal cancer.

Intriguingly, the researchers also delineated the complex feedback loops between hnRNP A1 and metabolic signaling pathways. hnRNP A1 appears to regulate not only fatty acid metabolism but also intersect with other metabolic networks, suggesting a broader role in cellular homeostasis. Decoding these interactions could provide a systemic framework for understanding cancer metabolism at large.

From a molecular perspective, hnRNP A1’s role extends beyond metabolism. It modulates the splicing of alternative transcripts relevant to oncogenic pathways, subtly tuning cellular phenotypes that favor tumor suppression. This pleiotropic nature reinforces hnRNP A1’s position as a master regulator in the cellular environment, defining it as a target of high translational potential.

The emerging concept from this research posits that metabolic enzymes traditionally viewed solely as catalytic actors are, in fact, under tight post-transcriptional governance by RNA-binding proteins like hnRNP A1. This regulatory axis offers a fresh vantage point from which to understand the metabolic plasticity that cancer cells exploit, potentially revealing vulnerabilities hitherto unrecognized.

Importantly, the findings open avenues for combinatorial therapies integrating metabolic inhibitors with agents that modulate RNA-binding protein activity. This dual-target approach could amplify therapeutic responses and circumvent resistance mechanisms that tumors develop against monotherapies.

Although these discoveries mark a significant advance, several questions remain. The precise structural motifs within hnRNP A1 responsible for its interaction with fatty acid metabolism-related mRNAs are yet to be fully characterized. Additionally, the impact of hnRNP A1 on other aspects of tumor microenvironment, such as immune evasion and stromal interactions, warrants further exploration.

This research stands at the confluence of molecular biology, cancer metabolism, and RNA biology, exemplifying how interdisciplinary approaches yield new dimensions in cancer understanding. The integration of transcriptomic, metabolic, and proteomic analyses in this study provides a robust platform for future investigations poised to convert molecular insights into effective clinical strategies.

In summary, the comprehensive elucidation of hnRNP A1 as a metabolic regulator mediating colorectal cancer suppression represents a landmark achievement. These findings herald a new horizon in cancer biology where metabolic pathways interlace with RNA stability mechanisms, inviting innovative therapeutic targeting strategies. As colorectal cancer continues to impose global health burdens, such translational research nourishes hope for refined treatments that improve patient outcomes beyond current standards.

Subject of Research: The role of hnRNP A1 in colorectal cancer tumorigenesis and progression through regulation of fatty acid metabolism and RNA stability.

Article Title: hnRNP A1 inhibits colorectal cancer tumorigenesis and progression by regulating fatty acid metabolism and RNA stability.

Article References:
Ji, K., Zhou, L., Zhang, T. et al. hnRNP A1 inhibits colorectal cancer tumorigenesis and progression by regulating fatty acid metabolism and RNA stability. Cell Death Discov. 11, 542 (2025). https://doi.org/10.1038/s41420-025-02814-0

Image Credits: AI Generated

DOI: 24 November 2025

The molecular rationale behind BMS-986504’s mechanism of action hinges on the metabolic consequences of MTAP loss within cancer cells. MTAP deficiency results in accumulation of methylthioadenosine (MTA), a metabolite that normally undergoes enzymatic breakdown mediated by MTAP. Elevated intracellular levels of MTA have significant biological implications, particularly concerning their interaction with protein arginine methyltransferase 5 (PRMT5), an enzyme essential for post-translational modification of target proteins involved in gene expression regulation, RNA splicing, and cellular survival pathways. BMS-986504 selectively targets the PRMT5 enzyme when it is bound by accumulated MTA, thereby inhibiting its function in MTAP-deleted cells while sparing normal tissues where this complex does not exist.

This therapeutic strategy represents a sophisticated form of synthetic lethality, exploiting the metabolic derangements caused by specific genetic deletions present in approximately 10-15% of all human cancers. Within this subset, NSCLC stands out as a disease with a notable prevalence of MTAP deletion, comprising up to 27% of these cases. The clinical trial evaluated BMS-986504 in a cohort of patients with advanced solid tumors harboring homozygous MTAP deletions, with NSCLC patients forming the majority group. Results indicated a substantial overall response rate of 29%, meaning nearly one-third of patients experienced significant tumor shrinkage or stable disease as a result of the therapy.

Importantly, the drug’s activity extended to patients bearing well-known oncogenic drivers such as EGFR mutations and ALK rearrangements, both of which often become refractory to existing tyrosine kinase inhibitors (TKIs). Among the NSCLC cohort evaluated, responses were observed in four out of seven EGFR-positive patients and two out of four ALK-positive patients, suggesting that BMS-986504 could provide clinical benefit even in otherwise treatment-resistant molecular subtypes. Additionally, one out of three patients with squamous histology responded, indicating a potential broad spectrum of efficacy across histological variants.

The durability of responses to BMS-986504 is noteworthy. The median duration of response extended to over 10 months, highlighting the agent’s capacity not only to induce tumor regression but to maintain disease control over several treatment cycles. Patients generally achieved responses within approximately four months of initiating therapy, underscoring a relatively swift onset of clinical benefit. Median follow-up for these outcomes reached nearly a year, lending confidence to the stability and sustainability of the observed effects.

Safety and tolerability profiles are critical considerations in the development of any anticancer agent, particularly in populations often burdened by multiple prior therapies and associated comorbidities. BMS-986504 demonstrated a favorable safety profile, with the majority of treatment-related adverse events (TRAEs) confined to mild or moderate gradations (grades 1 and 2). Though 14% of solid tumor patients experienced more severe (grade ≥3) TRAEs, hematologic toxicities were reportedly manageable, with treatment-related anemia, neutropenia, and thrombocytopenia occurring in manageable frequencies. No new or unexpected safety signals emerged across tumor types included in the study, which encompassed not only NSCLC but also mesothelioma, pancreatic ductal adenocarcinoma, and cholangiocarcinoma.

From a biochemical and pharmacological standpoint, the selectivity of BMS-986504 arises from its ability to distinguish the PRMT5 enzyme depending on its biochemical milieu. In normal cells, where MTAP and consequently MTA levels are intact and low, PRMT5 functions unimpeded and remains uninhibited by the drug. Conversely, in MTAP-deleted cancer cells, the buildup of MTA forms an aberrant complex with PRMT5, which the drug targets effectively. This selectivity reduces off-target effects and enhances the therapeutic window, a hallmark feature of precision medicine paradigms. Such targeted approaches are crucial for improving efficacy while reducing toxicity inherent in more generalized cytotoxic therapies.

The encouraging activity and safety results from this phase 1 trial have naturally propelled BMS-986504 into further clinical investigation. Two pivotal studies are currently underway assessing its utility in advanced NSCLC patients with MTAP deletions. One study evaluates the safety and efficacy of BMS-986504 as monotherapy in patients who have already exhausted prior lines of treatment. Another randomized controlled trial explores its integration into first-line therapy, combining it with the immune checkpoint inhibitor pembrolizumab and chemotherapy, compared against standard regimens. These trials will be instrumental in establishing not only the drug’s clinical efficacy in larger populations but also its optimal use in combination strategies aimed at maximizing patient benefit.

The underlying biology of PRMT5’s role in cancer underscores the broader significance of this therapeutic approach. PRMT5-mediated methylation regulates diverse cellular processes including transcriptional repression, RNA splicing, and cell cycle progression—all pathways frequently dysregulated in oncogenesis. By disrupting this enzymatic function within a metabolically compromised environment characterized by MTA accumulation, BMS-986504 interferes with tumor-promoting activities at a fundamental level. This represents a potent example of rational drug design informed by molecular oncology and metabolomics.

Moreover, MTAP deletion has emerged as an actionable biomarker with implications beyond lung cancer, with deletions detected in varied malignancies such as mesothelioma and pancreatic cancer. The concept of targeting vulnerabilities associated with loss-of-function mutations or deletions expands the therapeutic landscape, providing hope for patients with historically intractable cancers. The progress of BMS-986504 sets a precedent for future agents designed to exploit cancer-specific metabolic and enzymatic alterations.

Collectively, these exciting clinical findings and scientific insights mark a significant milestone in lung cancer research. They exemplify the promise of precision oncology, marrying detailed genetic and metabolic tumor profiling with the development of highly selective, mechanism-based pharmacologic interventions. The field awaits the continued maturation of data from ongoing trials with great anticipation, hopeful that BMS-986504 will establish a new standard of care for patients afflicted with MTAP-deleted NSCLC and potentially other solid tumors harboring similar vulnerabilities.

Subject of Research: BMS-986504, a PRMT5-MTA targeting agent in MTAP-deleted non-small cell lung cancer
Article Title: Promising Antitumor Activity of BMS-986504 in MTAP-Deleted Non-Small Cell Lung Cancer: Insights from the IASLC 2025 World Conference on Lung Cancer
News Publication Date: September 8, 2025
Web References:
– ClinicalTrials.gov identifiers NCT06855771 and NCT07063745
– International Association for the Study of Lung Cancer: www.iaslc.org
Keywords: Lung cancer, non-small cell lung cancer, MTAP deletion, PRMT5 inhibitor, targeted therapy, precision oncology, methylthioadenosine, BMS-986504, oncology clinical trials, EGFR mutations, ALK rearrangements, phase 1 clinical trial